Results 11 to 20 of about 2,318,223 (338)

MDT Treatment of Small Cell Lung Cancer Complicated with Adenocarcinoma: 
A Case Report and Literature Review

open access: yesChinese Journal of Lung Cancer, 2021
Small cell lung cancer (SCLC) is the most malignant lung cancer with the highest mortality. At present, the first-line standard treatment is still based on Etoposide and Platinum chemotherapy.
Zihan QU   +5 more
doaj   +1 more source

Immunotherapy of lung cancer: An update [PDF]

open access: yes, 2006
In Germany lung cancer is the leading cause of cancer-associated death in men. Surgery, chemotherapy and radiation may enhance survival of patients suffering from lung cancer but the enhancement is typically transient and mostly absent with advanced ...
Aman MJ   +36 more
core   +1 more source

Characteristics and outcome of patients with newly diagnosed advanced or metastatic lung cancer admitted to intensive care units (ICUs) [PDF]

open access: yes, 2018
BACKGROUND: Although patients with advanced or metastatic lung cancer have poor prognosis, admission to the ICU for management of life-threatening complications has increased over the years.
A Steven   +36 more
core   +2 more sources

Symptom trajectories during chemotherapy in patients with non‐small cell lung cancer (NSCLC) and the function of prolonging low dose dexamethasone in promoting enhanced recovery after chemotherapy

open access: yesThoracic Cancer, 2021
Background Lung cancer, mainly non‐small cell lung cancer (NSCLC), is one of the leading causes of death worldwide. Currently, chemotherapy is still the most significant treatment strategy for NSCLC.
Jinghao Liu   +11 more
doaj   +1 more source

RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets. [PDF]

open access: yes, 2016
RRx-001 is a pan-active, systemically nontoxic epigenetic inhibitor under investigation in advanced non-small cell lung cancer, small-cell lung cancer and high-grade neuroendocrine tumors in a Phase II clinical trial entitled TRIPLE THREAT (NCT02489903),
Brzezniak, Christina   +12 more
core   +3 more sources

EGFR-TKI ADR Management Chinese Expert Consensus

open access: yesChinese Journal of Lung Cancer, 2019
ErbB receptor tyrosine kinase inhibitors (EGFR-TKI), gefitinib, erlotinib, icotinib and aftinib, which are approved as a frontline treatment for patients with non-small cell lung cancer (NSCLC) who have tumors harboring EGFR mutations in China.
Chinese Society of Lung Cancer, Chinese Anti-Cancer Association
doaj   +1 more source

Lung Cancer [PDF]

open access: yesActa Oncologica, 1996
This synthesis of the literature on radiotherapy for lung cancer is based on 80 scientific articles, including 2 meta-analyses, 29 randomized studies, 19 prospective studies, and 21 retrospective studies. These studies involve 28172 patients. Basic treatment for limited-stage small cell lung cancer (SCLC), is chemotherapy.
openaire   +2 more sources

EML4-ALK-mediated activation of the JAK2-STAT pathway is critical for non-small cell lung cancer transformation

open access: yesBMC Pulmonary Medicine, 2021
Background The echinoderm microtubule-associated protein-like-4 anaplastic lymphoma kinase (EML4-ALK) fusion gene was identified in a subset of non-small cell lung cancer (NSCLC) patients. They responded positively to ALK inhibitors.
Ying Li   +6 more
doaj   +1 more source

Cyclooxygenase-2 Inhibitor: A Potential Combination Strategy With Immunotherapy in Cancer

open access: yesFrontiers in Oncology, 2021
The clinical application of immunotherapy is the milestone of cancer treatment. However, some patients have bad reaction. Cyclooxygenase-2 (COX-2) is frequently expressed in multiple cancer cells and is associated with poor prognosis.
Dan Pu   +8 more
doaj   +1 more source

Personalized Risk Assessment in Never, Light, and Heavy Smokers in a prospective cohort in Taiwan. [PDF]

open access: yes, 2016
The objective of this study was to develop markedly improved risk prediction models for lung cancer using a prospective cohort of 395,875 participants in Taiwan.
Chow, Wong-Ho   +14 more
core   +1 more source

Home - About - Disclaimer - Privacy